title: A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing!
abstract: BACKGROUND
  A limited body of research suggests that ongoing maintenance enteral nutrition (MEN) can be beneficial in maintaining disease remission in Crohn's Disease (CD). We aimed to assess how achievable MEN is and whether it helps to prolong remission.
  
  
  METHODS
  Patients newly diagnosed with CD in 2010 and 2011 who commenced exclusive enteral nutrition (EEN) for 8 weeks were followed up for a year post diagnosis. All patients who took EEN were encouraged to continue MEN post EEN. Data on azathioprine use was also collected. Categorical variables were compared using chi-square/Fischer's exact test. Medians were expressed along with complete data ranges.
  
  
  RESULTS
  59 patients (34 male, median age 11.07 years, range 2.5-16.33 years) were identified. 11/59 (18%) had a poor response to EEN and were switched to steroids. 48/59 patients completed 8 weeks EEN and achieved clinical remission/response. 46/48 patients received Modulen IBD®, 29/48 (60%) consumed EEN orally and 19/48 (40%) via NGT. 15/48 (31%) patients were able to continue MEN post EEN completion. MEN was consumed for a mean of 10.8 months (range 4-14 months). 14/15 patients drank MEN and 1/15 had MEN via NGT. Remission rates at 1 year in patients continuing MEN were 60% (9/15) compared to 15% (2/13) in patients taking no treatment (p = 0.001) and 65% (13/20) in patients taking azathioprine (p = 0.14).
  
  
  CONCLUSIONS
  A sub group of patients can continue MEN as a maintenance treatment and this seems a useful strategy, especially in those who are not commencing azathioprine.
authors.affiliation: Department of Nutrition & Dietetics, Yorkhill Hospital Glasgow, Dalnair Street, Glasgow G3 8SJ, United Kingdom. hazel.duncan4@nhs.net.
authors.forename: Hazel
authors.initials: H
authors.lastname: Duncan
authors.forename: Elaine
authors.initials: E
authors.lastname: Buchanan
authors.forename: Tracey
authors.initials: T
authors.lastname: Cardigan
authors.forename: Vikki
authors.initials: V
authors.lastname: Garrick
authors.forename: Lee
authors.initials: L
authors.lastname: Curtis
authors.forename: Paraic
authors.initials: P
authors.lastname: McGrogan
authors.forename: Andrew
authors.initials: A
authors.lastname: Barclay
authors.forename: Richard K
authors.initials: RK
authors.lastname: Russell
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003424:Crohn Disease / Q000628:therapy*; D004750:Enteral Nutrition / Q000379:methods*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies; D062606:Tertiary Care Centers; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D001379:Azathioprine